Systematic review and Meta-analysis on randomized controlled trial of efficacy and safety for acupuncture versus Flunarizine in treatment of migraine.
10.19540/j.cnki.cjcmm.20200521.502
- Author:
Min JIA
1
;
Yun-Ling ZHANG
2
;
L U YAN
2
;
Xing LIAO
3
;
Xiao LIANG
2
;
Jing-Jing WEI
4
;
Qian CHEN
5
;
Fu GUO-JING
5
;
Lin LEI
5
Author Information
1. Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
2. Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
3. Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
4. Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China Graduate School, Beijing University of Chinese Medicine Beijing 100029, China.
5. Graduate School, Beijing University of Chinese Medicine Beijing 100029, China.
- Publication Type:Systematic Review
- Keywords:
Flunarizine;
GRADE system;
Meta-analysis;
acupuncture;
migraine;
systematic review
- MeSH:
Acupuncture Therapy;
Flunarizine/therapeutic use*;
Humans;
Migraine Disorders/therapy*;
Treatment Outcome
- From:
China Journal of Chinese Materia Medica
2020;45(21):5083-5092
- CountryChina
- Language:Chinese
-
Abstract:
To systematically evaluate the efficacy and safety of acupuncture versus Flunarizine hydrochloride in the treatment of migraine. Four Chinese databases(CNKI, VIP, WanFang, CBM), three English databases(Cochrane Library, EMbase, Medline) and ClinicalTrail.gov were systematically and comprehensively retrieved. The retrieval time was from the establishment of each database to January 8, 2020. Randomized controlled trial(RCT) for acupuncture versus Flunarizine in the treatment of migraine were screened out according to inclusion criteria and exclusion criteria. The included studies were evaluated with the Cochrane bias risk assessment tool. The included studies was conducted by RevMan 5.3, and the outcome indicators were evaluated for evidence quality and strength of recommendation by the GRADE system. A total of 1 033 literatures were retrieved, and 23 studies were finally included. Except for 4 multiarm tests, the total sample size was 1 548, including 785 in acupuncture group and 763 in Flunarizine group. The overall quality of the included studies was not high. Meta-analysis results showed that the acupuncture group was superior to the Flunarizine group in reduction of headache frequency(SMD=-1.00, 95%CI[-1.45,-0.54], P<0.000 1). In reduction of headache intensity, acupuncture group was superior to Flunarizine group(SMD=-1.05, 95%CI[-1.41,-0.68], P<0.000 01). In reduction of headache duration, acupuncture group was superior to Flunarizine group(SMD=-1.42, 95%CI[-1.83,-1.02], P<0.000 1). The acupuncture group was superior to Flunarizine group(MD=-0.17, 95%CI[-0.21,-0.13], P<0.000 01) in reduction of the painkillers taking frequency. The acupuncture group was superior to Flunarizine group(SMD=-0.94, 95%CI[-1.35,-0.52], P<0.000 1) in allevia-tion of paroxysmal symptoms, such as nausea and vomiting. The GRADE system showed that the evidence level of the above indicators was extremely low, and the strength of recommendation was low. As for the occurrence of adverse reactions, the adverse reactions reported in the acupuncture group included in the study were all mild adverse reactions, like drowsiness, subcutaneous bleeding, local pain, subcutaneous hematoma and dizziness needle. The available evidence showed that acupuncture has a better efficacy than Flunarizine hydrochloride in the treatment of migraine in adult patients. However, due to the high bias risk in the included studies, the conclusions of this study shall be adopted with caution, and more high-quality studies shall be carried out for verification in the future.
